Resources
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II.
Infection prevention and control principles and recommendations for Ebola virus disease
This document is to describe actions and measures recommended to protect healthcare workers (HCWs) and others who may come in contact with Ebola virus, or patients with suspected or confirmed Ebola virus disease (EVD).
Life Saving Drugs Program – Fabry disease – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Fabry disease.
Life Saving Drugs Program – Gaucher disease (type 1) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of enzyme replacement medicines under the Life Saving Drugs Program medicines for Gaucher disease (type 1).
National Strategic Action Plan for Arthritis
The National Strategic Action Plan for Arthritis aims to guide national efforts to address the burden of arthritis.
National Strategic Action Plan for Inflammatory Bowel Disease
The National Strategic Action Plan for Inflammatory Bowel Disease (IBD) provides a path to better care, better quality of life and reduced burden of IBD for the Australian community.
National Strategic Action Plan for Childhood Heart Disease
The National Strategic Action Plan for Childhood Heart Disease (CHD) aims to reduce the impact of this condition in Australia. It outlines priority areas and actions to help people with CHD live longer, healthier and more productive lives.
National Strategic Action Plan for Lung Conditions
The National Strategic Action Plan for Lung Conditions outlines an evidence-based approach to reducing the burden of lung conditions in Australia.
Healthy ageing: developmental research report
We commissioned a market research study into healthy ageing, identifying how we can help encourage Australians to make the most of their later years.
Population-based screening framework
This framework sets out the principles of screening programs for cancer and chronic diseases. It informs decision makers about the key issues to consider when deciding whether to introduce a screening program.
National Action Plan for Endometriosis
This National Action Plan for Endometriosis acknowledges that endometriosis causes a substantial health burden in Australia. It sets goals and objectives to address this burden.
Tackling Indigenous Smoking program – Final evaluation report – July 2018
This report, completed in July 2018, evaluates how effective the Tackling Indigenous Smoking (TIS) program has been and whether it’s on target to achieve its long-term goals.
Procedure guidance for medicines funded through the Life Saving Drugs Program (LSDP)
This guidance document outlines our process and associated timelines to consider medicines seeking funding through the LSDP. It helps sponsors to prepare an application to make an ultra-rare disease medicine available on the LSDP.
Ensuring the future sustainability of the Life Saving Drugs Program
This agreement between the Government and Medicines Australia (MA) facilitates cooperation between them to ensure the future sustainability of the Life Saving Drugs Program.
Newborn Bloodspot Screening – National Policy Framework
The Newborn Bloodspot Screening National Policy Framework guides the national policies needed to support the ongoing success of newborn bloodspot screening in Australia.
National Asthma Strategy 2018
This National Asthma Strategy 2018 outlines a national response to asthma. It identifies the most effective and appropriate interventions to reduce the impact of asthma in the community.
Implementation plan for the Australian National Diabetes Strategy 2016–2020
This plan — Diabetes in Australia: Focus on the Future — outlines ways to implement the Government's Australian National Diabetes Strategy 2016–2020.
Skin cancer screening – position statement
The Standing Committee on Screening endorses recommendations provided in Cancer Council Australia’s 2014 position statement about why we don’t have a skin cancer screening program in Australia.
Australian National Diabetes Audit (ANDA)
Every year, the Australian National Diabetes Audit (ANDA) collects and reports on diabetes-related data from specialist diabetes centres across Australia.
National Cancer Screening Register – privacy impact assessment
This report looked at privacy issues relating to the National Cancer Screening Register. It contains 28 recommendations for the department.
Advice to the Government on the Development of the Australian National Diabetes Strategy 2016–2020
The Australian Government based the Australian National Diabetes Strategy 2016–2020 on the framework provided in this report.
Public Health and Chronic Disease Grant Program guidelines
The Public Health and Chronic Disease Grant program started on 1 July 2016. These guidelines outline the types of activities that this program funds, and how they are administered.
Australian National Diabetes Strategy 2016–2020
The Australian Government has developed a new national diabetes strategy. This strategy updates and prioritises the response to diabetes for all governments.
Evaluation of the diabetes care project
The Diabetes Care Project was a 3-year pilot program that analysed new models of health care delivery for adults with type 1 and type 2 diabetes.
Discussion paper on the late effects of polio/post-polio syndrome
Australian Government response to the House of Representatives Standing Committee on Health and Ageing report: Discussion paper on the late effects of polio/post-polio syndrome
Date last updated: